Strumento inattivo

Altre lingue ImmunoCellular Therapeutics Ltd Nyse

Azioni

US4525361055

Prezzo di chiusura Nyse Altri mercati azionari
- ^USD	-

2023	EOM Pharmaceutical Holdings annuncia i risultati principali del suo studio clinico Covid-19 con Eom613 in Brasile	CI
2023	EOM Pharmaceuticals Holdings, Inc. ha ritirato la sua IPO per un importo di 15 milioni di dollari.	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

EOM Pharmaceutical Holdings Provides an Update on its Lead Drug Candidate EOM613	07/11
EOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in Brazil	06/09/23
EOM Pharmaceutical Holdings Announces Topline Results of Its Covid-19 Clinical Trial of Eom613 in Brazil	06/09/23
EOM Pharmaceuticals Holdings, Inc. has withdrawn its IPO in the amount of $15 million.	02/08/23
EOM Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	20/12/22
ImmunoCellular Therapeutics Ltd. has Changed its Name to EOM Pharmaceuticals Holdings, Inc	10/11/22
EOM Pharmaceuticals Holdings, Inc. announced that it has received $0.75 million in funding	12/09/22
EOM Pharmaceuticals Holdings, Inc. announced a financing transaction	26/08/22
EOM Pharmaceuticals Holdings, Inc. has filed an IPO in the amount of $25 million.	24/06/22
ImmunoCellular Therapeutics, Ltd. Auditor Raises 'Going Concern' Doubt	24/06/22
ImmunoCellular Therapeutics, Ltd. Auditor Raises 'Going Concern' Doubt	10/02/22
EOM Pharmaceuticals, Inc. And Immunocellular Therapeutics, Ltd. Announce Entry Into And Close Of Definitive Merger Agreement	02/12/21
EOM Pharmaceuticals, Inc. acquired ImmunoCellular Therapeutics, Ltd. in a reverse merger transaction.	02/12/21
ImmunoCellular Therapeutics : Announces Application for Continued Public Quoting on the Over-the-Counter (OTC) Market	28/06/21
ImmunoCellular Therapeutics, Ltd.(AMEX:IMUC) dropped from S&P TMI Index	18/10/18
ImmunoCellular Therapeutics, Ltd. Announces Executive Changes, Effective October 15, 2018	15/10/18
ImmunoCellular Therapeutics, Ltd. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2018	16/08/18
ImmunoCellular Therapeutics Is Considering Strategic Alternatives	13/08/18
ImmunoCellular Therapeutics, Ltd. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2018	14/05/18
ImmunoCellular Therapeutics, Ltd. Announces Achievement of Next Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program	12/04/18

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue ImmunoCellular Therapeutics Ltd Nyse

Azioni

US4525361055

Altre lingue

Filtri